Moffitt Cancer Center researchers have identified a gene that may better predict survival for pancreatic adenocarcenoma, the fourth leading cause of cancer death in the United States.
Dr. Richard Kim, an assistant member of the Experimental Therapeutics Program and other researchers, studied the role of a gene involved in helping target gemcitabine, a commonly used chemotherapy in pancreatic cancer, according to a statement.
The retrospective study focused on 122 patients. A validation study would be necessary before clinical application of the research findings.
Kim worked with researchers from Cleveland Clinic, Case Western Reserve University School of Medicine, Veridex LLC, and Johnson & Johnson Co. on the study.
Moffitt, located in Tampa, is a National Cancer Institute-designated comprehensive cancer center.